BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 – 10.
Excerpt from:
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Related Post
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - November 27th, 2024
- Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - November 27th, 2024
- Fate Therapeutics to Present at Upcoming December Investor Conferences - November 27th, 2024
- Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- 89bio to Participate in the 7th Annual Evercore HealthCONx Conference - November 27th, 2024
- Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 - November 27th, 2024
- Fulcrum Therapeutics to Participate in Upcoming December Conferences - November 27th, 2024
- Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 - November 27th, 2024
- Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO - November 27th, 2024
- Fortrea to Present at the Citi Global Healthcare Conference - November 27th, 2024
- NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - November 27th, 2024
- Fortrea to Present at the Evercore HealthCONx Conference - November 27th, 2024
- ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Idorsia enters into exclusive negotiations for global rights to aprocitentan - November 27th, 2024
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of... - November 27th, 2024
- 142,701 Orion Corporation A shares converted into B shares - November 27th, 2024
- Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant... - November 3rd, 2024
- Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 - November 3rd, 2024
- Skye Bioscience to Announce Third Quarter 2024 Results - November 3rd, 2024
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - November 3rd, 2024
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 3rd, 2024
- Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - November 3rd, 2024
- TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update - November 3rd, 2024
- Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial - November 3rd, 2024
- Galecto Reports Third Quarter 2024 Financial Results - November 3rd, 2024
- Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - November 3rd, 2024
- Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results - November 3rd, 2024
- Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - November 3rd, 2024
- Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and... - November 3rd, 2024
- Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - November 3rd, 2024
- Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on... - November 3rd, 2024
- Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - November 3rd, 2024
- Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - November 3rd, 2024
- Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - November 3rd, 2024
- NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update - November 3rd, 2024
- ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer... - November 3rd, 2024
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - October 6th, 2024
- Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - October 6th, 2024
- Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer - October 6th, 2024
- Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - October 6th, 2024
- BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - October 6th, 2024
- Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - October 6th, 2024
- NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - October 6th, 2024
- TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - October 6th, 2024
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - October 6th, 2024
- Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - October 6th, 2024
- Major Shareholder Announcement - October 6th, 2024
- Altamira Therapeutics Provides Update on Nasdaq Listing - October 6th, 2024
- Trevena Announces Receipt of Nasdaq Delisting Notification - October 6th, 2024
- Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant - October 6th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 6th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 6th, 2024
- Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - October 6th, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 6th, 2024
- OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - October 6th, 2024
- Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda - October 6th, 2024
- Celldex Therapeutics to Present at Upcoming Investor Conferences - September 13th, 2024
- NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences - September 13th, 2024
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 13th, 2024
- One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations - September 13th, 2024
- Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company - September 13th, 2024
- Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs - September 13th, 2024
- Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 - September 13th, 2024
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in... - September 13th, 2024
- Immunocore to present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros - September 13th, 2024
- Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC - September 13th, 2024
- XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - September 13th, 2024
- Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- MBX Biosciences Announces Pricing of Initial Public Offering - September 13th, 2024
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy - September 13th, 2024
- Valneva Announces the Success of its Private Placement Raising approximately €60 Million - September 13th, 2024
- Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO - September 13th, 2024